The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Granulomatosis With Polyangiitis Treatment Market Expected To Scale Between 2026 And 2030?
The granulomatosis with polyangiitis treatment market has experienced substantial expansion in recent years. This market is anticipated to rise from $2.55 billion in 2025 to $2.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.9%. Historically, the market’s growth can be linked to the increased recognition of autoimmune diseases, the widespread availability of corticosteroids, the provision of hospital nephrology services, the utilization of immunosuppressive drugs, and the adoption of diagnostic imaging.
The granulomatosis with polyangiitis treatment market size is projected for significant expansion in the coming years. This market is anticipated to reach $3.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this growth during the forecast period include advancements in biologic drugs, targeted autoimmune therapies, enhanced early diagnostic screening, the rising need for chronic disease management, and the proliferation of specialty clinics. Key trends shaping this period encompass the expanded adoption of biologic treatments, a heightened focus on early diagnosis of autoimmune conditions, the development of strategies for extended disease remission, the increasing application of combination immunosuppressive treatments, and improved methods for monitoring organ damage.
Access Your Free Sample Report For In-Depth Market Analysis:
What Primary Drivers Are Shaping The Granulomatosis With Polyangiitis Treatment Market?
The expanding occurrence of autoimmune diseases is anticipated to fuel the expansion of the granulomatosis with polyangiitis treatment market in the coming years. Autoimmune conditions arise when the body’s defense system mistakenly targets its own healthy cells and tissues, causing inflammation and harm across various organs. The escalating prevalence of these diseases can be attributed to environmental factors like infections, chemicals, or pollutants, as well as shifts in lifestyle. Granulomatosis with polyangiitis treatment provides support for autoimmune diseases by employing immunosuppressive treatments such as corticosteroids and cyclophosphamide, which are effective in managing inflammation and averting organ damage. This makes timely intervention and customized therapies vital for handling other autoimmune conditions that operate through similar pathways. For example, a report from the Office for National Statistics, a UK-based government department, indicated in June 2023 that the worldwide count of individuals with multiple sclerosis (MS), an autoimmune disease, reached 2.9 million in 2023, an increase from 2.8 million in 2022. Consequently, the rising incidence of autoimmune diseases is propelling the growth of the granulomatosis with polyangiitis treatment market.
Which Segments Define The Granulomatosis With Polyangiitis Treatment Market Segment Structure?
The granulomatosis with polyangiitis treatment market covered in this report is segmented –
1) By Drug Type: Steroids, Immunosuppressants, Other Drug Types
2) By Route Of Administration: Oral, Intravenous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Steroids: Prednisone, Methylprednisolone, Dexamethasone, Hydrocortisone
2) By Immunosuppressants: Cyclophosphamide, Methotrexate, Azathioprine, Mycophenolate mofetil, Rituximab
3) By Other Drug Types: Plasma Exchange Therapy, Intravenous Immunoglobulin (IVIG), Biologic Agents, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
What Trends Are Affecting The Growth Of The Granulomatosis With Polyangiitis Treatment Market?
Major companies within the granulomatosis with polyangiitis treatment market are concentrating on developing innovative products, such as oral corticosteroids, to provide patients with more effective treatment options that improve disease management while minimizing the long-term side effects of steroid use. Oral corticosteroids are medications that reduce inflammation and suppress the immune system. They are frequently used to treat allergies, autoimmune diseases, and inflammatory disorders. For instance, in October 2024, AstraZeneca plc, a UK-based pharmaceutical company, announced that Fasenra (bevacizumab) had been approved in the European Union, a Europe-based political and economic union of European countries, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This approval follows positive results from the MANDARA Phase III trial, which demonstrated Fasenra’s efficacy in achieving remission and reducing reliance on oral corticosteroids in EGPA patients.
Who Are The Established Players Within The Granulomatosis With Polyangiitis Treatment Market?
Major companies operating in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F Hoffmann La Roche Ltd, Sanofi S A, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, ChemoCentryx Inc, Medac Pharma Inc, InflaRx GmbH, AbbVie Inc, Johnson & Johnson, Bristol Myers Squibb Company, Novartis AG, Biogen Inc, Takeda Pharmaceutical Company Limited, UCB S A, Bayer AG, Merck & Co Inc, Eli Lilly and Company, Astellas Pharma Inc
Get The Full Granulomatosis With Polyangiitis Treatment Market Report:
Which Region Leads The Granulomatosis With Polyangiitis Treatment Market In Terms Of Market Share?
North America was the largest region in the granulomatosis with polyangiitis treatment market in 2025. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Granulomatosis With Polyangiitis Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Granulomatosis With Polyangiitis Treatment Market 2026, By The Business Research Company
Zoonotic Disease Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/zoonotic-disease-treatment-global-market-report
Giant Cell Arteritis Market Report 2026
https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report
Nasal Polyps Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/nasal-polyps-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model